Evidence map›Paper›PMID 38095348›Full record

ArticleDrug delivery2023

Application of mPEG-CS-cRGD/

Xiaoyan Xu, Tianhao Zhou, Xudong Wei, Xuelian Jiang, Jiyan Cao

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Advanced drug delivery platforms target cancer stem cells.Asian journal of pharmaceutical sciences · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiaoyan XuDepartment of E.N.T, Gansu Provincial Hospital, Lanzhou, P.R. China.
Tianhao ZhouDepartment of E.N.T, Gansu Provincial Hospital, Lanzhou, P.R. China.
Xudong WeiDepartment of E.N.T, Gansu Provincial Hospital, Lanzhou, P.R. China.
Xuelian JiangDepartment of E.N.T, Gansu Provincial Hospital, Lanzhou, P.R. China.
Jiyan CaoDepartment of E.N.T, Gansu Provincial Hospital, Lanzhou, P.R. China.
Gansu University of Traditional Chinese Medicine · CNGansu Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although surgery-based comprehensive therapy is becoming the main approach to treat laryngeal cancer, recurrence, metastasis, radiotherapy resistance and chemotherapy tolerance are still the main causes of death in patients. Targeted inhibition of laryngeal cancer stem cells has been considered as the consensus to cure laryngeal cancer. Our previous study has confirmed proto-oncogene

Indexed as

Laryngeal NeoplasmsNanoparticlesAnimalsCell Line, TumorHumansMiceNeoplasm Recurrence, LocalNeoplastic Stem CellsPaclitaxelPolyethylene GlycolsRNA, Small InterferingPaclitaxelPolyethylene GlycolsRNA, Small InterferingBmi-1cancer stem cellscRGD peptidelaryngeal cancernanoparticlespaclitaxel

Identifiers

PMID38095348
PMCPMC9946312
OpenAlexW4321455175

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.